WallStSmart

Agios Pharm (AGIO)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Agios Pharm generates 8801% more annual revenue ($66.05M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. AGIO earns a higher WallStSmart Score of 40/100 (D).

AGIO

Hold

40

out of 100

Grade: D

Growth: 8.0Profit: 2.5Value: 6.7Quality: 8.5
Piotroski: 2/9Altman Z: 5.91

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AGIOUndervalued (+50.6%)

Margin of Safety

+50.6%

Fair Value

$56.09

Current Price

$28.29

$27.80 discount

UndervaluedFair: $56.09Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AGIO4 strengths · Avg: 9.5/10
Revenue GrowthGrowth
137.7%10/10

Revenue surging 137.7% year-over-year

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
5.9110/10

Safe zone — low bankruptcy risk

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

AGIO4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.75B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : AGIO

The strongest argument for AGIO centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 137.7% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : AGIO

The primary concerns for AGIO are EPS Growth, Market Cap, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

AGIO profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

AGIO is growing revenue faster at 137.7% — sustainability is the question.

AGIO generates stronger free cash flow (-120M), providing more financial flexibility.

Bottom Line

AGIO scores higher overall (40/100 vs 24/100) and 137.7% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agios Pharm

HEALTHCARE · BIOTECHNOLOGY · USA

Agios Pharmaceuticals, Inc., a biopharmaceutical company, is dedicated to drug discovery and development in the field of cellular metabolism and adjacent areas of biology. The company is headquartered in Cambridge, Massachusetts.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?